Navigation Links
Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Date:4/11/2008

TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Targeting mutant p53 protein and tumor vasculature: An effective

combination therapy for advanced breast tumors" (Abstract #2341, New

Targets 1: Mechanisms Session) - Poster session scheduled for Monday,

April 14, 2008 from 8:00 am to 12:00 pm.

-- "An immunocytokine that binds to phosphatidylserine generates an

effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor

Vaccines Session) - Poster session scheduled for Monday, April 14,

2008 from 1:00 pm to 5:00 pm.

-- "Combination of a monoclonal anti-phosphatidylserine antibody with

docetaxel strongly inhibits the growth and metastasis of

hormone-refractory prostate cancers in mice" (Abstract #2551, New

Approaches to Biological Therapy Session) - Oral presentation

scheduled for Monday, April 14, 2008 at 2:10 pm.

-- "Antibody targeting of phosphatidylserine produces a cytokine

microenvironment that enhances innate anti-tumor immune responses"

(Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 from

8:00 am to 12:00 pm.

Abstracts and information about the AACR and its Annual Meeting may be found at http://www.aacr.org.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
2. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
3. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
8. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
9. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:6/23/2017)... and ITHACA, N.Y. , June 23, ... University, a leader in dairy research, today announced a ... to help reduce the chances that the global milk ... of this dairy project, Cornell University has become the ... the Food Supply Chain, a food safety initiative that ...
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricityâ„¢ products, including ... EMR. These new integrations will ...
Breaking Biology News(10 mins):